Research programme: Natural killer cell-based therapeutics - BeiGene
Latest Information Update: 08 Mar 2024
At a glance
- Originator BeiGene
- Developer BeiGene; Shoreline Biosciences
- Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer; Unspecified
Most Recent Events
- 01 Mar 2024 Shoreline Biosciences and BeiGene terminates its exclusive worldwide strategic collaboration to develop and commercialise a portfolio of NK-based cell therapeutics
- 10 Jun 2021 Shoreline Biosciences and BeiGene enters into an exclusive worldwide strategic collaboration to develop and commercialise a portfolio of NK-based cell therapeutics
- 10 Jun 2021 Early research in Cancer in China (Parenteral)